Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Holdings Decreased by Deutsche Bank AG

Deutsche Bank AG reduced its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 84.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 44,052 shares of the company's stock after selling 238,010 shares during the period. Deutsche Bank AG owned about 0.07% of Larimar Therapeutics worth $170,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fi3 FINANCIAL ADVISORS LLC grew its stake in shares of Larimar Therapeutics by 16.7% during the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company's stock valued at $92,000 after buying an additional 3,411 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Larimar Therapeutics by 12.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock valued at $137,000 after buying an additional 3,877 shares during the period. Bank of America Corp DE grew its stake in shares of Larimar Therapeutics by 8.1% during the 4th quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock valued at $206,000 after buying an additional 3,980 shares during the period. SG Americas Securities LLC grew its stake in shares of Larimar Therapeutics by 35.1% during the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock valued at $75,000 after buying an additional 5,042 shares during the period. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Larimar Therapeutics during the 4th quarter valued at $25,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Trading Up 1.7%

LRMR stock traded up $0.04 during trading on Wednesday, reaching $2.45. The stock had a trading volume of 558,404 shares, compared to its average volume of 781,226. Larimar Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $11.20. The company has a market capitalization of $156.87 million, a P/E ratio of -2.13 and a beta of 0.93. The firm has a fifty day moving average price of $2.10 and a 200 day moving average price of $3.32.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). Sell-side analysts predict that Larimar Therapeutics, Inc. will post -1.15 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Guggenheim restated a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Robert W. Baird reduced their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Finally, HC Wainwright lifted their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, March 25th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $19.67.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.